PharmacoEconomics

, Volume 17, Issue 4, pp 331–338 | Cite as

Economic Burden of Irritable Bowel Syndrome

Proposed Strategies to Control Expenditures
  • Michael Camilleri
  • Donald E. Williams
Review Article

Abstract

It has been suggested that the annual direct costs for irritable bowel syndrome (IBS) are now around $US41 billion in the 8 most industrialised countries. This paper reviews the data on calculations of direct costs. The true economic burden is unclear, as there are insufficient data on indirect costs other than absenteeism from work and intangible costs cannot be estimated, particularly since presenters with IBS constitute only a subset of the patients with such symptoms in the community. Strategies to reduce direct costs must include physician and patient education, paramedical-based education and therapy, lay support groups, early consideration of psychosocial issues and psychological treatments, avoidance of unnecessary investigations and optimising the doctor-patient relationship. Indirect and intangible costs could be effectively reduced by novel, effective (not only efficacious) therapies.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Talley NJ, Gabriel SE, Harmsen WS, et al. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995; 109: 1736-41PubMedCrossRefGoogle Scholar
  2. 2.
    Fullerton S. Functional digestive disorders (FDD) in the year 2000: economic impact. Eur J Surg 1998; Suppl. 582: 62-4Google Scholar
  3. 3.
    Patrick DL, Drossman DA, Frederick IO, et al. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998; 43: 400-11PubMedCrossRefGoogle Scholar
  4. 4.
    Hahn BA, Kirchdoerfer LJ, Fullerton S, et al. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol Ther 1997; 11: 553-9PubMedCrossRefGoogle Scholar
  5. 5.
    Chassany O, Marquis P, Scherrer B, et al. Validation of a specific quality of life questionnaire for functional digestive disorders. Gut 1999; 44: 527-33PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders: prevalence, sociodemography, and health impact. Dig Dis Sci 1993; 38: 1569-80PubMedCrossRefGoogle Scholar
  7. 7.
    Hahn BA, Yan S, Strassels S. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Digestion 1999; 60: 77-81PubMedCrossRefGoogle Scholar
  8. 8.
    Wells NE, Hahn BA,Whorwell PJ. Clinical economics review: irritable bowel syndrome. Aliment Pharmacol Ther 1997; 11: 1019-30PubMedCrossRefGoogle Scholar
  9. 9.
    Thompson WG, Heaton KW, Smyth GT, et al. Irritable bowel syndrome: the view from general practice. Eur J Gastroenterol Hepatol 1997; 9: 689-92PubMedCrossRefGoogle Scholar
  10. 10.
    Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel. BMJ 1978; 2: 653-4PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders [letter]. Gastroenterology 1987; 92: 1282-4PubMedGoogle Scholar
  12. 12.
    Karampela K, Lacey L, Hahn B, et al. Costs associated with healthcare resource use and productivity loss in patients with irritable bowel syndrome (IBS) [abstract]. Gastroenterology 1999; 116: A69Google Scholar
  13. 13.
    Zinn C. Women consume far more of health budget than expected. BMJ 1998; 317: 838PubMedCentralCrossRefGoogle Scholar
  14. 14.
    Parsons ME, Garner A. Drug development in gastroenterology: the changing view of industry. Aliment Pharmacol Ther 1995; 9: 457-63PubMedCrossRefGoogle Scholar
  15. 15.
    Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5HT3-receptor antagonist. Aliment Pharmacol Ther 1999; 13: 1149-59PubMedCrossRefGoogle Scholar
  16. 16.
    Prather CM, Camilleri M, ZinsmeisterAR, et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology. In pressGoogle Scholar
  17. 17.
    Bouras EP, Camilleri M, Burton DD, et al. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999; 44: 682-6PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Dapoigny M, Abitbol JL, Fraitag B. Efficacy of peripheral kappa agonist, fedotozine, versus placebo in treatment of irritable bowel syndrome. Amulticenter dose-response study. Dig Dis Sci 1995; 40: 2244-9CrossRefGoogle Scholar
  19. 19.
    Drossman DA, Corazziari E, Talley NJ, et al. Rome II: a multinational consensus document on functional gastrointestinal disorders. Gut 1999; 45 Suppl. II: 1-81Google Scholar
  20. 20.
    Longstreth GF. Irritable bowel syndrome: diagnosis in the managed care era. Dig Dis Sci 1997; 42: 1105-11PubMedCrossRefGoogle Scholar
  21. 21.
    Freston JW. Successful practice in a managed care environment: managing costs while managing care. Gastroenterology 1996; 111: 516-8PubMedCrossRefGoogle Scholar
  22. 22.
    Longstreth GF, Wolde-Tsadik G. Irritable bowel-type symptoms in HMO examinees: prevalence, demographics, and clinical correlates. Dig Dis Sci 1993; 38: 1581-9PubMedCrossRefGoogle Scholar
  23. 23.
    Longstreth GF. Irritable bowel syndrome and chronic pelvic pain. Obstet Gynecol Surv 1994; 49: 505-7PubMedCrossRefGoogle Scholar
  24. 24.
    Longstreth GF, Preskill DB, Youkeles L. Irritable bowel syndrome in women having diagnostic laparoscopy or hysterectomy: relation to gynecologic features and outcome. Dig Dis Sci 1990; 35: 1285-90PubMedCrossRefGoogle Scholar
  25. 25.
    Camilleri M, Thompson WG, Fleshman JW, et al. Clinical management of intractable constipation. Ann Intern Med 1994; 121: 520-8PubMedCrossRefGoogle Scholar
  26. 26.
    Surrenti E, Rath DM, Pemberton JH, et al. Audit of constipation in a tertiary referral gastroenterology practice. Am J Gastroenterol 1995; 90: 1471-5PubMedGoogle Scholar
  27. 27.
    Colwell LJ, Prather CM, Phillips SF, et al. Effects of an irritable bowel syndrome educational class on health-promoting behaviors and symptoms. Am J Gastroenterol 1998; 93: 901-5PubMedCrossRefGoogle Scholar
  28. 28.
    Drossman DA. Diagnosing and treating patients with refractory functional gastrointestinal disorders. Ann Intern Med 1995; 123: 688-97PubMedCrossRefGoogle Scholar
  29. 29.
    Blanchard EB. Psychological treatment of irritable bowel syndrome. Prof Psychol Res Pract 1996; 27: 241-4CrossRefGoogle Scholar
  30. 30.
    Camilleri M, Prather CM. The irritable bowel syndrome: mechanisms and a practical approach to management. Ann Intern Med 1992; 116: 1001-8PubMedCrossRefGoogle Scholar
  31. 31.
    Drossman DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997; 112: 2120-37PubMedCrossRefGoogle Scholar
  32. 32.
    MacIntosh DG, Thompson WG, Patel DG, et al. Is rectal biopsy necessary in irritable bowel syndrome? Am J Gastroenterol 1992; 87: 1407-9PubMedGoogle Scholar
  33. 33.
    Longstreth GF. Irritable bowel syndrome: a multibillion-dollar problem. Gastroenterology 1996; 111: 833-4Google Scholar
  34. 34.
    Francis CY, Duffy JN, Whorwell PJ, et al. Does routine abdominal ultrasound enhance diagnostic accuracy in irritable bowel syndrome? Am J Gastroenterol 1996; 91: 1348-50PubMedGoogle Scholar
  35. 35.
    St. John DJ, Bond JH, et al. Prevention of colorectal cancer: guidelines based on new data (WHO Collaborating Center for the Prevention of Colorectal Cancer). Bull World Health Organ 1995; 73: 7-10PubMedCentralPubMedGoogle Scholar
  36. 36.
    Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997; 112: 594-642PubMedCrossRefGoogle Scholar
  37. 37.
    Bond JH. Screening guidelines for colorectal cancer. Am J Med 1999; 106: 7S-10SPubMedCrossRefGoogle Scholar
  38. 38.
    Alvarez WC. Help in sizing up the patient. In: Alvarez WC, editor. Nervousness, indigestion and pain. New York: Hoeber Publishing Co., 1943: 83-99Google Scholar
  39. 39.
    Bentkover JD, Field C, Greene EM, et al. The economic burden of irritable bowel syndrome in Canada [abstract]. Gastroenterology 1998; 114: A720CrossRefGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  • Michael Camilleri
    • 1
  • Donald E. Williams
    • 2
  1. 1.Gastroenterology Research UnitMayo Clinic and Mayo FoundationRochesterUSA
  2. 2.Section of Behavioural MedicineMayo Clinic and Mayo FoundationRochesterUSA

Personalised recommendations